Cancer
Researchers at Vitro Diagnostics, Inc., a leading biopharmaceutical company, have made significant breakthroughs in adult stem cell products and technology, with applications in cell-based therapy for cancer. The development of novel stem cell technology and products may lead to novel cell therapy for cancer, including treatment of currently untreatable cancer
Cancer
Scientists in Toronto, Canada, have shed light on the mechanisms behind the toxicity and resistance to anticancer therapies involving cisplatin and oxaliplatin. Research conducted by T.J. Preston and colleagues has revealed that oxidative DNA damage, particularly the 7,8-dihydro-8-oxo2'-deoxyguanosine (8-oxodG) lesion, plays a crucial role in the
Cancer research
A team of researchers in Japan has discovered that the compound (-)-epigallocatechin gallate (EGCG), found in green tea, downregulates the epidermal growth factor receptor (EGFR) in colon cancer cells by inducing phosphorylation at Ser1046/1047 via the p38 mitogen-activated protein kinase (MAPK) pathway. This finding provides new insights into
Drugs
Investigators in the United States conducted preclinical biodistribution studies with INGN 007, an oncolytic adenovirus vector, in Syrian hamsters and mice to support an early-stage clinical trial. The study examined vector dissemination and pharmacokinetics following intravenous administration in nine tissues and blood at five time points spanning one year. The
Drugs
Researchers in the United States have discovered that MLH1 deficiency significantly enhances tumor cell sensitivity to ganciclovir, a crucial finding in the field of cancer gene therapy. By employing HSV-TK and ganciclovir, scientists have observed a unique pattern of delayed cytotoxicity in S-phase cells. The study suggests that MLH1, an
Pharmaceutical industry
Amgen's denosumab, a monoclonal antibody that targets the RANK Ligand pathway, has demonstrated significant efficacy in reducing fracture risk in women with postmenopausal osteoporosis and men with prostate cancer undergoing androgen deprivation therapy (ADT). Two pivotal Phase 3 studies, published in The New England Journal of Medicine, investigated
Pharmaceutical industry
Researchers in the United States have characterized in vitro models for alkaline phosphatase (ALP)-mediated phosphate prodrug conversion, a common approach to circumventing poor solubility issues of parent drugs. The study evaluated fosphenytoin and fosfluconazole as probe prodrugs in rat intestine mucosa scraps, human colon carcinoma (Caco-2) cells, and Madin-Darby
Drugs
Researchers from the Medical University of South Carolina have discovered a new approach to treating malignant peripheral nerve sheath tumors (MPNST), a disease that affects approximately 10% of neurofibromatosis type-1 patients and is a major contributing factor to their mortality and morbidity. The study found that small hyaluronan oligosaccharides can
Drugs
A recent study published in Molecular Cancer Therapeutics has highlighted the potential of Src tyrosine kinase as a target for anticancer therapy, particularly in pancreatic cancer. Researchers in the United States investigated the in vivo efficacy and pharmacodynamic effects of bosutinib, a Src/Abl inhibitor, using a panel of human
Pharmaceutical industry
Inovio Biomedical Corporation, a leader in DNA vaccine design, development, and delivery, has announced a registered direct offering of $30 million in securities. The company will sell 11,111,110 shares of its common stock and warrants to purchase up to 2,777,776 additional shares of its common stock
Pharmaceutical industry
Allos Therapeutics, Inc., a biopharmaceutical company, has received notification from the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) that they will hold a meeting on September 2, 2009, to review the company's New Drug Application (NDA) for pralatrexate. The NDA was submitted
Cancer
Scientists in Chongqing, People's Republic of China, have made a significant discovery in the field of cancer research. They have identified a novel multi-drug resistance gene, HA117, which significantly increases the drug resistance of chronic myelogenous leukemia cell line K562. The researchers found that expression of the HA117
